UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY. Click to learn about TGTX growth, upcoming trials, and ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Children most affected by MS-related biological aging appeared to be aging up to two years faster than kids without MS, even ...

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...

Source Reference: Fox RJ, et al "Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis" N Engl J Med 2025; DOI: 10.1056/NEJMoa2415988. Secondary Source New England Journal of Medicine ...

Multiple sclerosis (MS) is a chronic, lifelong condition for which there is no cure. It causes progressive, irreversible disability, and many symptoms including pain, chronic fatigue, unsteady gait, ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.” Dr Fox is a paid advisor to ...

Between Oct. 23, 2020, and Jan. 12, 2023, the randomized, double-blind, placebo-controlled trial enrolled 1,131 patients ages 18-60 at 264 sites across 31 countries.